CureVac has raised an additional €27M ($29.5M) that will help the company keep on its track to be the first one to launch a mRNA therapy, a technology that can revolutionize how drugs are designed.
CureVac is a German company in the billion-euro biotech club at the forefront of messenger RNA (mRNA) therapies, a technology that can instruct the body to produce its own drug. The company has just announced a €27M ($29.5M) round from local investors that adds up to a total €325M raised.
Without being actively looking for new funding, the company is now adding extra cash to its last year’s €100M funding, which included the Bill & Melinda Gates Foundation. The reason for its success is that CureVac is the most advanced company developing mRNA therapies, being the only one to reach Phase IIb so far. Its leading candidate is a prostate cancer vaccine, while other drugs in the pipeline target non-small cell lung cancer (NSCLC), rabies,